What are the key takeaways from this a16z Podcast episode?

Key insights include: **Personalization is mechanistically required, not optional:** Roughly 90% of the tumor antigens selected for each patient's vaccine differ from those of other patients. This means shared-antigen approaches used in prior cancer vaccine trials were structurally flawed. Researchers and investors evaluating cancer immunotherapy platforms should treat individualization as a baseline requirement, not a premium feature.; **mRNA's immune-system advantage over protein/peptide vaccines:** When injected intramuscularly, Moderna's mRNA enters antigen-presenting cells in the lymph nodes and translates from within, generating T-cell education at the cellular level. Prior cancer vaccine failures used protein or peptide approaches that circulated in the bloodstream without this internal immune-cell presentation mechanism, explaining over 1,000 failed trials.; **Needle-to-needle manufacturing cycle is currently 42 days:** Moderna produces each personalized dose by receiving sequencing data as a digital file, synthesizing DNA enzymatically without E. coli or plasmid reactors, then encapsulating mRNA in lipid nanoparticles. The fully synthetic, water-based process uses compact machines rather than large bioreactors, enabling the Marlborough, Massachusetts facility to produce tens of thousands of unique doses annually.

What did Stephane Banzel discuss on a16z Podcast?

Moderna CEO Stephane Bancel discusses the Phase III trial results of mRNA-based personalized cancer vaccine mRNA-4157 (Intismeran), developed with Merck, showing 80% disease-free survival at five years in melanoma patients versus 60% with Keytruda alone, and outlines the manufacturing, regulatory, and expansion roadmap. Key topics include: **Personalization is mechanistically required, not optional:** Roughly 90% of the tumor antigens selected for each patient's vaccine differ from those of other patients. This means shared-antigen approaches used in prior cancer vaccine trials were structurally flawed. Researchers and investors evaluating cancer immunotherapy platforms should treat individualization as a baseline requirement, not a premium feature.; **mRNA's immune-system advantage over protein/peptide vaccines:** When injected intramuscularly, Moderna's mRNA enters antigen-presenting cells in the lymph nodes and translates from within, generating T-cell education at the cellular level. Prior cancer vaccine failures used protein or peptide approaches that circulated in the bloodstream without this internal immune-cell presentation mechanism, explaining over 1,000 failed trials..

How long is this episode of a16z Podcast?

This episode is 40 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

a16z Podcast

Inside Moderna’s Personalized Cancer Vaccine

September 2, 2026

40 min episode · 2 min read

Stephane Banzel

Episode

40 min

Read time

2 min

Topics

Investing, Leadership, Product & Tech Trends

AI-Generated Summary

Published Sep 2, 2026

Key Takeaways

✓Personalization is mechanistically required, not optional: Roughly 90% of the tumor antigens selected for each patient's vaccine differ from those of other patients. This means shared-antigen approaches used in prior cancer vaccine trials were structurally flawed. Researchers and investors evaluating cancer immunotherapy platforms should treat individualization as a baseline requirement, not a premium feature.
✓mRNA's immune-system advantage over protein/peptide vaccines: When injected intramuscularly, Moderna's mRNA enters antigen-presenting cells in the lymph nodes and translates from within, generating T-cell education at the cellular level. Prior cancer vaccine failures used protein or peptide approaches that circulated in the bloodstream without this internal immune-cell presentation mechanism, explaining over 1,000 failed trials.
✓Needle-to-needle manufacturing cycle is currently 42 days: Moderna produces each personalized dose by receiving sequencing data as a digital file, synthesizing DNA enzymatically without E. coli or plasmid reactors, then encapsulating mRNA in lipid nanoparticles. The fully synthetic, water-based process uses compact machines rather than large bioreactors, enabling the Marlborough, Massachusetts facility to produce tens of thousands of unique doses annually.
✓Regulatory approval covers the process, not individual doses: The FDA pathway for Intismeran follows a process Biologics License Application, the same model used for CAR-T therapies. The FDA's core requirement is demonstrating that identical input samples consistently produce equivalent output products across the full manufacturing pipeline, validating process robustness rather than approving each patient-specific batch individually.
✓Three clinical expansion vectors beyond melanoma are active: Moderna is running Phase III trials in lung cancer, Phase II trials in kidney and bladder cancers (all combined with Keytruda), a Phase III monotherapy trial in Stage 1 lung cancer without checkpoint inhibitors, and early-stage trials in pancreatic and gastric cancers where Keytruda has previously failed, targeting orthogonal mechanisms of action.

What It Covers

Moderna CEO Stephane Bancel discusses the Phase III trial results of mRNA-based personalized cancer vaccine mRNA-4157 (Intismeran), developed with Merck, showing 80% disease-free survival at five years in melanoma patients versus 60% with Keytruda alone, and outlines the manufacturing, regulatory, and expansion roadmap.

Key Questions Answered

•Personalization is mechanistically required, not optional: Roughly 90% of the tumor antigens selected for each patient's vaccine differ from those of other patients. This means shared-antigen approaches used in prior cancer vaccine trials were structurally flawed. Researchers and investors evaluating cancer immunotherapy platforms should treat individualization as a baseline requirement, not a premium feature.
•mRNA's immune-system advantage over protein/peptide vaccines: When injected intramuscularly, Moderna's mRNA enters antigen-presenting cells in the lymph nodes and translates from within, generating T-cell education at the cellular level. Prior cancer vaccine failures used protein or peptide approaches that circulated in the bloodstream without this internal immune-cell presentation mechanism, explaining over 1,000 failed trials.
•Needle-to-needle manufacturing cycle is currently 42 days: Moderna produces each personalized dose by receiving sequencing data as a digital file, synthesizing DNA enzymatically without E. coli or plasmid reactors, then encapsulating mRNA in lipid nanoparticles. The fully synthetic, water-based process uses compact machines rather than large bioreactors, enabling the Marlborough, Massachusetts facility to produce tens of thousands of unique doses annually.
•Regulatory approval covers the process, not individual doses: The FDA pathway for Intismeran follows a process Biologics License Application, the same model used for CAR-T therapies. The FDA's core requirement is demonstrating that identical input samples consistently produce equivalent output products across the full manufacturing pipeline, validating process robustness rather than approving each patient-specific batch individually.
•Three clinical expansion vectors beyond melanoma are active: Moderna is running Phase III trials in lung cancer, Phase II trials in kidney and bladder cancers (all combined with Keytruda), a Phase III monotherapy trial in Stage 1 lung cancer without checkpoint inhibitors, and early-stage trials in pancreatic and gastric cancers where Keytruda has previously failed, targeting orthogonal mechanisms of action.

Notable Moment

Bancel reveals that when Moderna began the individualized cancer vaccine program, the team had no idea what percentage of antigens would overlap between patients — expecting perhaps 2–5%. The actual result, 90% unique per patient, retroactively proved that every prior shared-antigen cancer vaccine trial was built on a false premise.

Know someone who'd find this useful?

Episode Transcript

It's the first time there is a cancer vaccine working. The field has been doing that for twenty plus years, more than a thousand clinical trials that have all failed. What was different this time? What is it about mRNA technology that enables the immune system to learn in a way that other approaches were unable. We all have cancer cells all the time in our body. Our immune system is very well trained to basically notice those cancer cells very early and get rid of them. But if your cancer grows, then the question is how you reteach the immune system. We're going to basically take a biopsy of your tumor, we're going read all the letters of its DNA, and then we're going to do the same things with the healthy cell of your body. And we're going to literally compare letter by letter, nucleotide by nucleotide, and then we're going to use an algorithm to identify which one of those mutations are the most relevant. And so when this is injected in your body, it teaches the immune system the signature of your cancer cell that it missed. What gets regulated here? Because every dose is different, so obviously every dose doesn't get approved. Basically, Jorge, what the FDA wants to know. Before Moderna's mRNA platform helped produce a COVID vaccine, the company was already working toward another goal: using mRNA to fight cancer. A decade later, that bet has reached a major milestone. A16Z general partner Jorge Conde sits down with Moderna CEO Stephane Banzel following positive Phase III results from Moderna and Merck's individualized mRNA treatment for melanoma. It's the culmination of a project Moderna has been working on for roughly a decade. Stephane explains how Moderna takes a patient's tumor, sequences it against their healthy cells, identifies the mutations unique to that cancer, and uses that information to manufacture a personalized mRNA designed to teach the immune system what to attack. And because roughly 90% of the selected antigens differ from one patient to another, personalization isn't an edge case. It's fundamental to how the treatment works. They also get into the extraordinary operational challenge behind this. How do you manufacture thousands of different medicines, one patient at a time, quickly and reliably enough to make personalized medicine work at scale? And finally, they look at where the platform could go next, from other cancers to rare genetic and autoimmune diseases. Hi. Welcome to the A16z Podcast. I'm Jorge Conde, a general partner on the A16z BioHealth team. I am thrilled today to welcome back Moderna CEO, Stephane Bonsell. For folks that have been longtime listeners may recall, Stephane joined us on the A6dz podcast back in December 2020 when we were talking about all of the work Moderna did to bring us the mRNA COVID vaccine. And at the time, if you can go back and listen to that episode, you'll hear how quickly Moderna was able to react to the existence of …

Get the full transcript (7,261 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all a16z Podcast transcripts →